GSK Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by GSK Plc, dated October 14, 2024, serves as a transaction notification for the month of October 2024. The document discloses share acquisitions by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) resulting from dividend reinvestment plans.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It strictly reports on specific equity transactions.
| Transaction Date | Instrument | Price per ADS | Total Volume |
|---|---|---|---|
| October 11, 2024 | American Depositary Shares (ADSs) | $39.0587 | 234 ADSs |
Note: Total volume is the aggregate of individual transactions listed below.
Material Changes and Transaction Details
The filing details the acquisition of ADSs by eight Independent Non-Executive Directors following the reinvestment of dividends paid on October 10, 2024. All transactions occurred on the New York Stock Exchange (XNYS) at a uniform price of $39.0587 per ADS.
- Elizabeth McKee Anderson: 16 ADSs
- Charles Bancroft: 105 ADSs
- Dr. Hal Barron: 19 ADSs
- Dr. Anne Beal: 14 ADSs
- Dr. Harry Dietz: 14 ADSs
- Dr. Jesse Goodman: 14 ADSs
- Dr. Jeannie Lee: 2 ADSs
- Dr. Vishal Sikka: 64 ADSs
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risk factors, or contingencies. It is a regulatory disclosure of insider trading activity compliant with Rule 13a-16 or 15d-16.
Investor Verification Checklist
- Verify the dividend payment date of October 10, 2024, to confirm the reinvestment trigger.
- Confirm the market price of GSK ADSs on October 11, 2024, to validate the transaction price of $39.0587.
- Review the company's Dividend Reinvestment Plan (DRIP) terms to understand the automatic acquisition mechanism.
- Check subsequent filings for any changes in director shareholdings beyond these specific transactions.